UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2007
| | Calypte Biomedical Corporation | |
| | (Exact name of Company as specified in its charter) | |
Delaware | 000-20985 | 06-1226727 |
(State or Other Jurisdiction)of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification) |
16290 S.W. Upper Boones Ferry Road, Portland, OR 97224
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (503) 726-2227
N/A
(Former name or former address, if changed since last report)
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(b) On November 16, 2007, the employment of Richard D. Brounstein, Executive Vice President of Calypte Biomedical Corporation, was terminated.
Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: Portland, Oregon
November 23, 2007
| | | |
| | Calypte Biomedical Corporation |
|
|
|
| | By: | /s/ Jerrold D. Dotson |
| |
Jerrold D. Dotson Vice President- Finance and Corporate Secretary |
| | |
